Use of Self-Collected Dried Blood Spots and a Multiplex Microsphere Immunoassay to Measure IgG Antibody Response to COVID-19 Vaccines.
Use of Self-Collected Dried Blood Spots and a Multiplex Microsphere Immunoassay to Measure IgG Antibody Response to COVID-19 Vaccines.
复制标题
DOI：
10.1128/spectrum.01336-22
复制
发表时间：
2023-02-14
影响因子：
3.7
通讯作者：
Styer, Linda M.
中科院分区：
文献类型：
--
作者：
Nemeth, Katherine L.;Yauney, Erica;Rock, Jean M.;Bievenue, Rachel;Parker, Monica M.;Styer, Linda M.
血清调查可以确定病原体在人群中的范围和传播。然而，采集静脉血需要经过培训的医务人员。干血斑 (DBS) 是一个合适的替代品，因为它们可以自行采集并在室温下储存/运输。随着 2021 年初开始部署 COVID-19 疫苗，我们迅速招募实验室员工参与一项研究，以评估疫苗接种后的 IgG 抗体水平。参与者收到了 DBS 收集套件、自我收集说明和一份简短的调查问卷。 168 名参与者在疫苗接种前和/或接种后每人收集了 3 个 DBS，并使用多重微球免疫测定 (MIA) 进行测试，该测定分别测量 SARS-CoV-2 刺突 S1 和核衣壳抗原的 IgG 抗体。大多数 DBS（99.6%，507/509）适合测试。既往感染过 SARS-CoV-2 的参与者 (n = 7) 在第一剂疫苗接种后产生了高 S 抗体水平。初次接受治疗的个体 (n = 161) 在第二次给药后达到了较高的 S 抗体水平。在接种 Moderna (n = 29) 和 Pfizer-BioNTech (n = 137) 疫苗的受试者中观察到相似的抗体水平。对于那些接受任一 mRNA 疫苗的人来说，在第一剂疫苗接种后局部副作用更常见，而在第二剂疫苗接种后全身副作用更常见。在第二剂疫苗接种前一周抗体水平最高的个体在第二剂疫苗接种时会出现更多副作用。我们的研究表明，将自行收集的 DBS 和多重 MIA 相结合是评估疫苗接种抗体水平的一种便捷有效的方法，并且可以轻松用于 SARS-CoV-2 或其他新出现病原体的人群血清调查。重要性 血清调查是评估人群免疫力的重要工具 (1, 2)。然而，有效血清调查的常见障碍，特别是在大流行期间，包括高成本、收集静脉血样本所需的资源、缺乏训练有素的实验室技术人员以及进行检测所需的时间。通过利用自行收集的干血斑 (DBS) 和我们之前开发的高通量微球免疫测定法，我们能够显着减少许多这些常见的挑战。参与者被要求在接种 COVID-19 疫苗之前和/或之后自行收集三个 DBS，以测量疫苗接种后的抗体水平。参与者成功收集了 507 个 DBS，并测试了针对 SARS-CoV-2 刺突蛋白和核衣壳蛋白的 IgG 抗体。当与自行收集的 DBS 一起使用时，我们相对低成本的检测方法显着减少了从人群中收集血清学数据的常见障碍，并且能够有效评估抗体对疫苗接种的反应。
Serosurveys can determine the extent and spread of a pathogen in populations. However, collection of venous blood requires trained medical staff. Dried blood spots (DBS) are a suitable alternative because they can be self-collected and stored/shipped at room temperature. As COVID-19 vaccine deployment began in early 2021, we rapidly enrolled laboratory employees in a study to evaluate IgG antibody levels following vaccination. Participants received a DBS collection kit, self-collection instructions, and a brief questionnaire. Three DBS were collected by each of 168 participants pre- and/or postvaccination and tested with a multiplex microsphere immunoassay (MIA) that separately measures IgG antibodies to SARS-CoV-2 spike-S1 and nucleocapsid antigens. Most DBS (99.6%, 507/509) were suitable for testing. Participants with prior SARS-CoV-2 infection (n = 7) generated high S antibody levels after the first vaccine dose. Naïve individuals (n = 161) attained high S antibody levels after the second dose. Similar antibody levels were seen among those vaccinated with Moderna (n = 29) and Pfizer-BioNTech (n = 137). For those receiving either mRNA vaccine, local side effects were more common after the first vaccine dose, whereas systemic side effects were more common after the second dose. Individuals with the highest antibody levels in the week prior to the second vaccine dose experienced more side effects from the second dose. Our study demonstrated that combining self-collected DBS and a multiplex MIA is a convenient and effective way to assess antibody levels to vaccination and could easily be used for population serosurveys of SARS-CoV-2 or other emerging pathogens. IMPORTANCE Serosurveys are an essential tool for assessing immunity in a population (1, 2). However, common barriers to effective serosurveys, particularly during a pandemic, include high-costs, resources required to collect venous blood samples, lack of trained laboratory technicians, and time required to perform the assay. By utilizing self-collected dried blood spots (DBS) and our previously developed high-throughput microsphere immunoassay, we were able to significantly reduce many of these common challenges. Participants were asked to self-collect three DBS before and/or after they received their COVID-19 vaccines to measure antibody levels following vaccination. Participants successfully collected 507 DBS that were tested for IgG antibodies to the spike and nucleocapsid proteins of SARS-CoV-2. When used with self-collected DBS, our relatively low-cost assay significantly reduced common barriers to collecting serological data from a population and was able to effectively assess antibody response to vaccination.
登录
查看更多内容
影响因子：
7.8
作者：
Amodio E;Capra G;Casuccio A;Grazia S;Genovese D;Pizzo S;Calamusa G;Ferraro D;Giammanco GM;Vitale F;Bonura F
通讯作者：
Bonura F
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.3390/diagnostics11030426
发表时间：
2021-03-03
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Dörschug A;Frickmann H;Schwanbeck J;Yilmaz E;Mese K;Hahn A;Groß U;Zautner AE
通讯作者：
Zautner AE
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
13.8
作者：
通讯作者：
--